Avadel is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.
Our focusNot an actual patient
LUMRYZTM (sodium oxybate) extended-release for oral suspension, Avadel’s once-at-bedtime narcolepsy drug candidate, granted tentative approval by the U.S. FDA
Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will have the most meaningful impact on those we serve. Join us and be part of a team that’s dedicated to making a difference.
Get in touchWith operations and employees across the US and beyond, we’re always on the lookout for energetic and passionate individuals who want to roll up their sleeves and join us in building our company, and together, making a meaningful difference in the lives of those with narcolepsy.
Read our latest news and events and find our stock and financial information, corporate governance, and shareholder services.
